FPRX

Bemarituzumab (FPA144)

Gastric/ Gastroesophageal Junction (GEJ) tumors

Stage (next event)

Next Event

Expected Date

Phase 3

Initiation

TBA

2021 priorities for the bemarituzumab program include collaborating with regulatory agencies on next steps, initiating a global Phase 3 trial in gastric and GEJ cancers and evaluating bemarituzumab in other epithelial cancers that overexpress FGFR2b

Catalyst Info & Data Links

MORE INFORMATION:

• All three efficacy endpoints (PFS, OS and ORR) in the FIGHT Phase 2 trial met pre-specified statistical significance

• 2021 priorities for the bemarituzumab program include collaborating with regulatory agencies on next steps, initiating a global Phase 3 trial in gastric and GEJ cancers and evaluating bemarituzumab in other epithelial cancers that overexpress FGFR2b

DRUG HISTORY:

• 01-15-2021 Phase 2 FIGHT Trial Results Presented at ASCO GI Validate Importance of FGFR2b Overexpression and Reinforce Potential of Bemarituzumab Plus Chemotherapy as a Frontline Targeted Treatment for FGFR2b+ Gastric and GEJ Cancers

• 12-09-2020 ASCO presentation announcement

• 11-10-2020 Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Survival Benefit Compared to Placebo Plus Chemotherapy in Front-Line Advanced Gastric and Gastroesophageal Junction Cancer

• 11-03-2020 Five Prime Therapeutics Reports Third Quarter 2020 Results

PRESENTATION

• 11-2020: Bemarituzumab Top Line Data Announcement

PRESENTATION

• 11-2020: Bemarituzumab Top Line Data Announcement

Mechanism of Action

Bemarituzumab (anti-FGFR2b) is a first-in-class isoform-selective antibody with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) being studied in the FIGHT trial as a targeted therapy for front-line FGFR2b+/HER2- gastric and gastroesophageal junction (GEJ) cancer.

HC (DV)

​

FPRX, Five Prime Therapeutics, Bemarituzumab (FPA144), 1L gastric/GEJ cancer,

Prior Data (click to view full image)

Trial Design / Revenue (click to view full image)